Genzyme Corp

Genzyme — Proxy Contest (June 2010)

24 slides from Genzyme's proxy contest presentation, Jun 7, 2010

  1. Slide 1: The Clayton Act Violation Caused by Icahn's Nominees – the Facts

    Genzyme The Clayton Act Violation Caused by Icahn’s Nominees – the Facts Response to Icahn’s June 4 Filings 1

  2. Slide 2: Summary

    Summary Icahn recognizes explicitly the potential for a Clayton Act violation as a result of the election of his nominees The June 4 Icahn filing reads: “the Icahn Parties are unable to confirm that a violation would not occur if Drs. Denner and Mulligan were elected to the [Genzyme] Board” In his p

  3. Slide 3: Icahn Accepts that Off-Label Sales Matter for Clayton Act Violations

    Icahn Accepts that Off-Label Sales Matter for Clayton Act Violations Prior Icahn position predicated on inaccurate assumption that competitive sales only occur in labeled indications Now, Icahn in his June 4th filing admits “there undoubtedly were some off-label US sales” And Icahn’s June 4th filing

  4. Slide 4: Icahn Substantially Understates the Level of Competition; Data Show a Violation

    Icahn Substantially Understates the Level of Competition; the Data Clearly Show that a Violation Exists The Icahn “analysis” is predicated on 2009 sales of Rituxan in CLL being less than $93.2 million A March 19, 2010 UBS research report estimates such sales exceed $650 million The Icahn “analysis”

  5. Slide 5: Recusal not a Viable Strategy

    Recusal not a Viable Strategy A violation of the Clayton Act cannot be overcome by a director not participating in discussions regarding the overlapping products The statute provides no ability to circumvent a violation through corporate governance steps 5

  6. Slide 6: Section of the Clayton Act Prohibits Individuals From Serving on Boards of Competitors

    Section 8 of the Clayton Act Prohibits Individuals From Simultaneously Serving on Boards of Competitors The law provides that no person shall, at the same time, serve as a director in any two corporations where: The two corporations are “engaged in whole or in part in commerce” The two corporations

  7. Slide 7: Important Information

    Important Information 7 On April 26, 2010, Genzyme filed a definitive proxy statement with the SEC in connection with the company’s 2010 annual meeting of shareholders. Genzyme shareholders are strongly advised to read carefully the company’s definitive proxy statement and other proxy materials befo

  8. Slide 8: Document 1A: Rituxan Prescribing Information

    DOCUMENT 1A 1.14.2.3 Final Labelling Text HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Rituxan safely and effectively. See full prescribing information for Rituxan. Rituxan (rituximab) Injection for Intravenous Use Initial U.S. Approval: 199

  9. Slide 9: Rituximab hospital use evaluation

    Until 2004, rituximab purchases were fairly stable, but between 2004 and 2005 they increased 78% at the hospital, and between 2005 and 2006 they increased 54%. At the same time, overall rituximab sales in the United States grew by double-digit percentages. John Esterly, a PharmD candidate, and his c

  10. Slide 10: Document 1C: Campath Prescribing Information

    DOCUMENT 1C HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Campath safely and effectively. See full prescribing information for Campath. Campath® (alemtuzumab) Injection for intravenous use Initial U.S. Approval: 2001 WARNING: CYTOPENIAS, INFU

  11. Slide 11: Document 1D: Fludara Prescribing Information

    DOCUMENT 1D FPO 6700101 Fludara® (fludarabine phosphate) FOR INJECTION FOR INTRAVENOUS USE ONLY Fix Only WARNING: FLUDARA FOR INJECTION should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy, FLUDARA FOR INJECTION can severely suppress

  12. Slide 12: Document 1F: Clolar Prescribing Information

    DOCUMENT 1F HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Clolar safely and effectively. See full prescribing information for Clolar. Clolar (clofarabine) Injection for intravenous use Initial U.S. Approval: 2004 INDICATIONS AND USAGE • Clola

  13. Slide 13: Document 1G: Thymoglobulin Prescribing Information

    DOCUMENT 1G Anti-thymocyte Globulin (Rabbit) Sterile Lyophilized Powder For Intravenous Use Only Rx only WARNING Thymoglobulin* should only be used by physicians experienced in immunosuppressive therapy for the management of renal transplant patients. DESCRIPTION Thymoglobulin* [Anti-thymocyte Globu

  14. Slide 14: Document 1H: Thymoglobuline Japan Package Insert

    DOCUMENT 1H Translation of Thymoglobuline PI Submitted to PMDA: May 14, 2008 Standard Commodity Classification No. of Japan 876399 -IMMUNOSUPPRESSANT- THYMOGLOBULINE® injection 25 mg <Anti-human thymocyte immunoglobulin, rabbit> Bilogical product, Powerful drug, Designated drug, Prescription drug: c

  15. Slide 15: Roche top marketed drugs – PharmaValues NPV Ready Reckoner

    Figure 5: Roche top 10 marketed drugs- PharmaValues NPV Ready Reckoner End User Sales $m Drug Indication Region Dev Lic Prob Launch Date Generic Entry 2009a 2010e 2011e 2012e 2013e 2014e 2015e Peak Sales $m Post Tax Margin $m NPV/shr (CHF) NPV % Total Avastin Cancer - Colorectal US M 100% 2004 1,156

  16. Slide 16: Patient Types Treated with Alemtuzumab

    PeopleMetrics Rx Patient Types Treated with Alemtuzumab a = The majority of alemtuzumab use is for CLL with smaller percentages of patients receiving it for NHL or conditioning prior to transplant Patient Types Treated with Alemtuzumab (Past Year) 100% wou om P sean £ com 3 mB cet Net 5 Lox a i ‘Ger

  17. Slide 17: Within-Product Market Share of Grams Sold by Patient Situation

    Within-Product Market Share of Grams Sold by Patient Situation (%) Neupogen and Leukine “within product” usage is similar for CIN. These products differ in that Leukine has what immunotherapy exists at present. According to these model-derived estimates, about 1 Leukine gram in 12 is used for prosta

  18. Slide 18: Tandem Cancer Audit Program Annual Patient Treatments

    DOCUMENT F Tandem Cancer Audit Program Annual Patient Treatments 12 Months Ending: 2009_11 Sampled Projected 14,583 Diagnosis (Major Mentions) CLL 60.2 % NHL 36.7 % AML 1.5 % MYELOMA 0.5 % HODGKINS 0.4 % ALL 0.3 % Synovate

  19. Slide 19: Fludarabine usage in the 5EU mostly in CLL

    60% of fludarabine usage in the 5EU is in CLL, with 27% of usage in NHL Fludarabine Annual Patient Treatments - SEU ‘poner saa. L| AML i ane oe acu [] Lass a 7 = iE] ea 2 re Free ceneny oon ony Transplant / Oncology Confidential

  20. Slide 20: Thymoglobulin 2009 sales by use

    HEM Rev $20 M 2009 Thymo $118M Other Induction ‘Acute Rejection Renal Induction 2009 Sales and based on 2010 PSUR calculations of vial allocations

  21. Slide 21: G5 Summary Transplant Market Mapping Project

    G5 Summary Transplant Market Mapping Project Country Analysis March 2008

  22. Slide 22: Countries included

    ore Ee el Countries included ° France * Germany «Italy * Spain e UK

  23. Slide 23: Thymoglobulin Sales in G5

    ‘Sales $000 genzyme 25.000 15,000, 5,000 HSCT — Thymo Sales — G5 ‘Source: Thymoglobulin Forecast Model ‘GPotental OThymo

  24. Slide 24: Important Information

    Important Information On April 26, 2010, Genzyme filed a definitive proxy statement with the SEC in connection with the company’s 2010 annual meeting of shareholders. Genzyme shareholders are strongly advised to read carefully the company’s definitive proxy statement and other proxy materials before

Genzyme — Proxy Contest (June 2010) on 6ix